Other Information.
+Added: (a) Disclosure in lieu of reporting on a Current Report on Form 8-K.
+Added: (b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.
+Added: (c) Insider Trading Arrangements and Policies.
+Added: During the three months ended March 31, 2024, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.
Number Description
5 unchanged sentences
001-39620) filed on January 7, 2022).
+Added: F orm of Pre- f unded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's C urrent Report on Form 8-K (File No.
+Added: 001-39620) filed on January 12, 2024
+Added: Form of Pre- f unded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No.
+Added: 001-39620) filed on March 29, 2024
+Added: P raxis Precision Medicines, Inc.
+Added: 2024 Inducement Plan and Forms of Award Agreements thereunder (incorporated by reference to the Registrant's Registration S tatement on Form S-8 (File No.
+Added: 333-276786 filed on January 31, 2024)
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
PRAXIS PRECISION MEDICINES, INC.
−Removed: November 7, 2023 By:
+Added: May 13, 2024 By:
/s/ Marcio Souza
Chief Executive Officer and Director (Principal Executive Officer)
−Removed: November 7, 2023 By:
+Added: May 13, 2024 By:
/s/ Timothy Kelly
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.